Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Echinacoside is a natural phenylethanoid glycoside first isolated from Echinacea angustifolia. It is currently being investigated for its anti-apoptotic, neuroprotective, antioxidant, anti-inflammatory, and cardiovascular effects. Preclinical studies suggest potential therapeutic applications in neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, as well as atherosclerosis, osteoporosis, acute colitis, wound healing, hepatitis, and certain cancers including endometrial cancer. Mechanistically, echinacoside has been shown to inhibit apoptosis and may exert its effects through modulation of the PI3K/Akt signaling pathway among others[1][4][6]. However, it suffers from poor bioavailability in its prototype form and lacks robust clinical trial evidence for any indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on echinacoside.